Help guide our efforts to modernize
Send us your comments by March 14, 2020. Menu

LN-145 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03449108
Recruitment Status : Recruiting
First Posted : February 28, 2018
Last Update Posted : January 6, 2020
Iovance Biotherapeutics, Inc.
National Cancer Institute (NCI)
Information provided by (Responsible Party):
M.D. Anderson Cancer Center

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : December 31, 2020
Estimated Study Completion Date : December 31, 2021